Favipiravir provides symptomatic relief from COVID, has mild side-effects, finds study by drug manufacturer
Results showed no new safety signals or concerns with the use of Favipiravir, and already-known side effects like weakness, gastritis, diarrhoea, vomiting etc were found to be mild in nature
Previous research has shown that this drug can reduce inflammation and sepsis in animals by blocking IL-6, a pro-inflammatory cytokine. Unregulated inflammation and cytokine storms are possible causes of mortality in severe COVID-19 patients
An inflammatory bowel disease is a group of disorders that leads to long term inflammation in the bowels, mostly colon and rectum.
Researchers warned that 'Favipiravir is not a panacea', since it wasn't specifically developed for coronaviruses.
Coronavirus Updates: Maharashtra reports 14,492 new COVID-19 cases, 326 deaths; tally rises to 6,43,289
Coronavirus LIVE Updates: As many as 26 volunteers who reached the Air-India Express plane crash site in Kozhikode evacuated the injured passengers on 7 August, have tested positive for COVID-19
Coronavirus LIVE Updates: The Maharashtra health department said that 11,514 COVID-19 cases and 316 deaths were reported in the state on Thursday. Total number of cases in the state is now at 4,79,779, including 1,46,305 active cases, 3,16,375 recovered and 16,792 deaths.
Zenara Pharma gets DCGI approval to sell Favipiravir tablet Favizen to treat mild to moderate COVID-19 infections
The company is in talks with various institutions to make the tablets available at discounted or no cost to underprivileged patients.
Lupin launches antiviral drug Favipiravir under the name Covihalt to treat mild to moderate COVID-19 infection
The Covihalt tablet will be available in 200 mg tablets in a strip of 10 and will cost Rs 49 per tablet in India.
Sunpharma launches Favipiravir tablet Fluguard to treat mild to moderate COVID-19 infections at Rs 35 per pill
Favipiravir is an antiviral drug that was originally made to treat influenza in Japan under the brand name Avigan.
COVID-19 treatment: Fabiflu by Glenmark, HCQ, Remdesivir and other drugs that are being used to treat coronavirus patients
Favipiravir is an antiviral drug which was developed by a Japanese pharma company, Fujifilm Toyama Chemical, to treat influenza.
Coronavirus Outbreak Updates: Madhya Pradesh govt to promote 1st, 2nd year UG students based on previous scores; 1,128 cases in Mumbai today
Coronavirus Outbreak LIVE Updates: Tamil Nadu reported 2,710 new COVID-19 cases and 37 deaths, taking the total number of cases to 62,087 and death toll to 794. Number of active cases stands at 27,178.
Glenmark claims that favipiravir showed improvement of up to 88 percent in mild to moderate COVID-19 cases.
Coronavirus Outbreak Updates: Confirmed cases in Mumbai surge to 66,507 as city reports 1,242 new infections; toll rises to 3,669 with 41 deaths
Coronavirus Outbreak Updates: Mumbai on Sunday recorded 1,242 new coronavirus positive cases and 41 deaths, taking the total positive cases to 66,507 and toll to 3,669.
Hetero gets DCGI nod to launch anti-viral drug Remdesivir under brand name Covifor for COVID-19 treatment
The drug has been granted approval by DCGI for the treatment of suspected or laboratory-confirmed cases of COVID-19 in adults and children, hospitalised with severe symptoms of the disease, the company said.
Indian regulators give Glenmark approval to manufacture, sell favipiravir for ‘restricted emergency use’ in treating COVID-19 patients
Glenmark Pharmaceuticals Ltd has received Indian regulatory approval to make and sell oral antiviral drug favipiravir for treating mild-to-moderate COVID-19 infections in the country
As there is no specific treatment for COVID-19, antibiotics are being used inappropriately to treat symptoms in people confirmed or suspected with COVID-19, increasing the chance of them developing resistant to the antimicrobial treatments
Japanese government gives up on gaining approval for Avigan after study show no evidence of efficacy in COVID-19
Concerns remain about Avigan, known generically as favipiravir, as it has been shown to cause birth defects in animal studies.
On 1 May, Glenmark Pharmaceuticals said it has become the first company in India to receive approval from Drug Controller General of India (DCGI) to conduct clinical trials of Favipiravir antiviral tablets for the treatment of COVID-19 patients.
Remdesivir mimics the genetic material of the coronavirus and prevents new virus copies from being produced.
Indian pharmaceutical company Strides Pharma Science Ltd said on Thursday it has got regulatory approval to conduct clinical trials of antiviral drug favipiravir, considered a potential treatment for COVID-19